Core Points - CSL Seqirus, in partnership with BARDA, will expand its MF59® adjuvant reserves to support U.S. pandemic preparedness efforts, increasing the inventory to the equivalent of 40 million doses through a $121.4 million multi-year award [1][2][3] Company Overview - CSL Seqirus is a major player in the global influenza vaccine market and is part of CSL (ASX: CSL), which has a diverse portfolio including treatments for hemophilia and immune deficiencies [7][9] - The company operates state-of-the-art production facilities in the U.S., U.K., and Australia, utilizing advanced technologies to produce a wide range of influenza vaccines [7][9] Industry Context - The MF59® adjuvant is crucial for pandemic preparedness as it enhances immune response while reducing the amount of antigen needed, thereby increasing the number of available vaccine doses [3][5] - The current public health risk from avian influenza A(H5) is low, but the CDC is monitoring the situation closely due to recent outbreaks in poultry and dairy cows [4][6] - Historical data indicates that pandemics can occur unpredictably, with the 1918 influenza pandemic being the most severe, resulting in an estimated 50 million deaths worldwide [5]
CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak